Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probenecid interaction study with sorafenib (PROSORA)
NL-OMON46801Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib and probenecid in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and well-differentiated thyroid cancer (WDTC), sponsored by Erasmus MC. Started Feb 2018; status: active, not recruiting.
02
Drugs
sorafenibprobenecid
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on NL-OMON46801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46801.